Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis

- Hughes, Jordana, Jokubaitis, Vilija, Lugaresi, Alessandra, Hupperts, Raymond, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand'Maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Ramo-Tello, Cristina, Trojano, Maria, Slee, Mark, Shaygannejad, Vahid, Boz, Cavit, Lechner-Scott, Jeanette, Van Pesch, Vincent, Pucci, Eugenio, Solaro, Claudio, Verheul, Freek, Terzi, Murat, Granella, Franco, Spitaleri, Daniele, Alroughani, Raed, Jun, Jae-Kwan, Fambiatos, Adam, Van der Walt, Anneke, Butzkueven, Helmut, Kalincik, Tomas

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

- Kalincik, Tomas, Jokubaitis, Vilja, Duquette, Pierre, Grammond, Pierre, Solaro, Claudio, Grand'Maison, Francois, Hupperts, Raymond, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Butler, Ernest, Spelman, Tim, Slee, Mark, Kermode, Allan, Fabis-Pedrini, Marzena, McCombe, Pamela, Barnett, Michael, Shaw, Cameron, Hodgkinson, Suzanne, Butzkueven, Helmut, MSBase Study Group,, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Lechner-Scott, Jeannette, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc

Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder

- Kunchok, Amy, Malpas, Charles, Ozakbas, Serkan, Olascoaga, Javier, Simo, Magdolna, Granella, Franco, Patti, Francesco, McCombe, Pamela, Csepany, Tundle, Singhal, Bhim, Bergamaschi, Roberto, Fragoso, Yara, Nytrova, Petra, Al-Harbi, Talal, Turkoglu, Recai, Lechner-Scott, Jeannette, Laureys, Guy, Oreja-Guevara, Celia, Pucci, Eugenio, Sola, Patrizia, Ferraro, Diana, Altintas, Ayse, Soysala, Aysun, Havrdova, Eva Kubala, Vucic, Steve, Grand'Maison, Francois, Izquierdo, Guillermo, Eichau, Sara, Lugaresi, Alessandra, Onofrj, Marco, Trojano, Maria, Marriott, Mark, Butzkueven, Helmut, Kister, Ilya, Alroughani, Raed, Kalincik, Tomas, Terzi, Murat, Yamout, Bassem, Hor, Jyh Yung, Karabudak, Rana, Boz, Cavit

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

- Kalincik, Tomas, Jokubaitis, Vilija, Grand'Maison, Francois, Pucci, Eugenio, Van Pesch, Vincent, Boz, Cavit, Iuliano, Gerardo, Fernandez-Bolanos, Ricardo, Flechter, Shlomo, Spitaleri, Daniele, Cristiano, Edgardo, Verheul, Ferek, Izquierdo, Guillermo, Lechner-Scott, Jeannette, Amato, Maria Pia, Cabrera-Gomez, Jose Antonio, Saladino, Maria Laura, Slee, Mark, Moore, Fraser, Gray, Orla, Paine, Mark, Barnett, Michael, Havrdova, Eva, Duquette, Pierre, Horakova, Dana, Spelman, Timothy, Trojano, Maria, Butzkueven, Helmut, Girard, Marc, Grammond, Pierre, Lugaresi, Alessandra, Oreja-Guevara, Celia, Bergamaschi, Roberto, Hupperts, Raymond

Comparative efficacy of first-line natalizumab vs IFN-ß or glatiramer acetate in relapsing MS

- Spelman, Tim, Kalincik, Tomas, Havrdová, Eva, Horáková, Dana, Grammond, Pierre, Duquette, Pierre, Prat, Alexandre, Iuliano, Gerardo, Terzi, Murat, Izquierdo, Guillermo, Hupperts, Raymond M.M., Jokubaitis, Vilija, Lechner-Scott, Jeannette, Zhang, Annie, Pellegrini, Fabio, Wiendl, Heinz, Belachew, Shibeshih, Hyde, Robert, Verheul, Freek, Lugaresi, Alessandra

Comparative efficacy of switching to natalizumab in active multiple sclerosis

- Spelman, Timothy, Kalincik, Tomas, Grand-Maison, Francois, Izquierdo, Guillermo, Grammond, Pierre, Duquette, Pierre, Lugaresi, Alessandra, Lechner-Scott, Jeannette, Oreja-Guevara, Celia, Hupperts, Raymond, Petersen, Thor, Barnett, Michael, Zhang, Annie, Trojano, Maria, Butzkueven, Helmut, Pellegrini, Fabio, Wiendl, Heinz, Kappos, Ludwig, Tsvetkova, Larisa, Belachew, Shibeshih, Hyde, Robert, Verheul, Freek

Defining secondary progressive multiple sclerosis

- Lorscheider, Johannes, Buzzard, Katherine, Prat, Alexandre, Lugaresi, Alessandra, Grand'Maison, François, Grammond, Pierre, Hupperts, Raymond, Alroughani, Raed, Sola, Patrizia, Boz, Cavit, Pucci, Eugenio, Lechner-Scott, Jeanette, Jokubaitis, Vilija, Bergamaschi, Roberto, Oreja-Guevara, Celia, Iuliano, Gerardo, Van Pesch, Vincent, Granella, Franco, Ramo-Tello, Cristina, Spitaleri, Daniele, Petersen, Thor, Slee, Mark, Verheul, Freek, Spelman, Tim, Ampapa, Radek, Amato, Maria Pia, McCombe, Pamela, Vucic, Steve, Sánchez Menoyo, José Luis, Cristiano, Edgardo, Barnett, Michael H., Hodgkinson, Suzanne, Olascoaga, Javier, Laura Saladino, Maria, Havrdova, Eva, Gray, Orla, Shaw, Cameron, Moore, Fraser, Butzkueven, Helmut, Kalincik, Tomas, Horakova, Dana, Trojano, Maria, Izquierdo, Guillermo, Girard, Marc, Duquette, Pierre

Fingolimod after natalizumab and the risk of short-term relapse

- Jokubaitis, Vilija G., Li, Vivien, Barnett, Michael, Grand'Maison, Francois, Trojano, Maria, Slee, Mark, Giuliani, Giorgio, Shaw, Cameron, Boz, Cavit, Spitaleri, Daniele L. A., Verheul, Freek, Haartsen, Jodi, Kalincik, Tomas, Liew, Danny, Butzkueven, Helmut, Izquierdo, Guillermo, Hodgkinson, Suzanne, Alroughani, Raed, Lechner-Scott, Jeannette, Lugaresi, Alessandra, Duquette, Pierre, Girard, Marc

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis

- Kalincik, Tomas, Spelman, Timothy, Grand’Maison, Francois, La Spitaleri, Daniele, Rio, Maria Edite, Flechter, Sholmo, Oreja-Guevara, Celia, Giuliani, Giorgio, Savino, Aldo, Amato, Maria Pia, Petersen, Thor, Fernandez-Bolanos, Ricardo, Trojano, Maria, Bergamaschi, Roberto, Iuliano, Gerardo, Boz, Cavit, Lechner-Scott, Jeannette, Duquette, Pierre, Izquierdo, Guillermo, Grammond, Pierre, Lugaresi, Alessandra, Hupperts, Raymond, Cristiano, Edgardo, Van Pesch, Vincent

Predictors of disability worsening in clinically isolated syndrome

- Jokubaitis, Vilija G., Spelman, Tim, Cabrera-Gomez, José, Oreja-Guevara, Celia, Boz, Cavit, Giuliani, Giorgio, Fernández-Bolaños, Ricardo, Iuliano, Gerardo, Lechner-Scott, Jeannette, Verheul, Freek, van Pesch, Vincent, Petkovska-Boskova, Tatjana, Kalincik, Tomas, Fiol, Marcela, Moore, Fraser, Cristiano, Edgardo, Alroughani, Raed, Bergamaschi, Roberto, Barnett, Michael, Slee, Mark, Vella, Norbet, Herbert, Joseph, Shaw, Cameron, Izquierdo, Guillermo, Saladino, Maria Laura, Amato, Maria Pia, Liew, Danny, Paolicelli, Damiano, Butzkueven, Helmut, Trojano, Maria, Grand'Maison, François, Duquette, Pierre, Girard, Marc, Lugaresi, Alessandra, Grammond, Pierre, Hupperts, Raymond

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

- Jokubaitis, Vilija G., Spelman, Tim, Grammond, Pierre, Van Pesch, Vincent, Pucci, Eugenio, Grand'Maison, François, Hupperts, Raymond, Granella, Franco, Sola, Patrizia, Bergamaschi, Roberto, Iuliano, Gerardo, Spitaleri, Daniele, Kalincik, Tomas, Lechner-Scott, Jeannette, Lorscheider, Johannes, Havrdova, Eva, Horakova, Dana, Duquette, Pierre, Girard, Marc, Prat, Alexandre, Izquierdo, Guillermo

Risk of relapse phenotype recurrence in multiple sclerosis

- Kalincik, Tomas, Buzzard, Katherine, Oreja-Guevara, Celia, Boz, Cavit, Hupperts, Raymond, Petersen, Thor, Giuliani, Giorgop, Iuliano, Gerardo, Lechner-Scott, Jeannette, Barnett, Michael, Bergamaschi, Roberto, Van Pesch, Vincent, Jokubaitis, Vilija, Amato, Maria Pia, van Munster, Erik, Fernandez-Bolanos, Ricardo, Verheul, Freek, Fiol, Marcela, Cristiano, Edgardo, Slee, Mark, Rio, Maria Edite, Spitaleri, Daniele, Alroughani, Raed, Trojano, Maria, Gray, Orla, Saladino, Maria Laura, Flechter, Sholmo, Herbert, Joseph, Cabrera-Gomez, Jose Antonio, Vella, Norbert, Paine, Mark, Shaw, Cameron, Moore, Fraser, Vucic, Steve, Duquette, Pierre, Savino, Aldo, Singhal, Bhim, Petkovska-Boskova, Tatjana, Parratt, John, Sirbu, Carmen-Adella, Rozsa, Csilla, Liew, Danny, Butzkueven, Helmut, Izquierdo, Guillermo, Girard, Marc, Lugaresi, Alessandra, Grammond, Pierre, Grand'Maison, Francois

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

- Kalincik, Tomas, Vivek, Vino, Bergamaschi, Roberto, Iuliano, Gerardo, Alroughani, Raed, Van Pesch, Vincent, Amato, Maria Pia, Slee, Mark, Verheul, Freek, Fernandez-Bolanos, Ricardo, Fiol, Marcela, La Spitaleri, Daniele, Jokubaitis, Vilija, Lechner-Scott, Jeannette, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Grand’Maison, Francois, Hupperts, Raymond, Oreja-Guevara, Celia

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

- Kalincik, Tomas, Horakova, Dana, Spelman, Tim, Jokubaitis, Vilija, Trojano, Maria, Lugaresi, Alessandra, Izquierdo, Guillermo, Rozsa, Csilla, Grammond, Pierre, Alroughani, Raed, Duquette, Pierre, Girard, Marc, Pucci, Eugenio, Lechner-Scott, Jeannette, Slee, Mark, Fernandez-Bolanos, Ricardo, Grand'Maison, Francois, Hupperts, Raymond, Verheul, Freek, Hodgkinson, Suzanne

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

- Kalincik, Tomas, Manouchehrinia, Ali, Girard, Marc, Prat, Alexandre, Duquette, Pierre, Grammond, Pierre, Sola, Patrizia, Hupperts, Raymond, Grand'Maison, Francois, Pucci, Eugenio, Boz, Cavit, Alroughani, Raed, Sobisek, Lukas, Lechner-Scott, Jeannette, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

- Kalincik, Tomas, Brown, J. William L., McGuigan, Christopher, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Robertson, Neil, Lechner-Scott, Jeannette, Willis, Mark, Scolding, Neil, Rice, Claire M., Wilkins, Alastair, Pearson, Owen, Ziemssen, Tjalf, Hutchinson, Michael